DDInter740 DDInter1016
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose]. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in patients with cirrhosis.[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Flecainide {u} (Compound) binds {v} (Gene) CYP2D6
Flecainide {u} (Compound) upregulates {v} (Gene) MTHFD2
Flecainide {u} (Compound) downregulates {v} (Gene) RRM2
Flecainide {u} (Compound) causes {v} (Side Effect) Shock
Flecainide (Compound) resembles Mefloquine (Compound)
Flecainide (Compound) binds CYP2D6 (Gene)
Flecainide (Compound) upregulates MTHFD2 (Gene)
Flecainide (Compound) downregulates RRM2 (Gene)
Flecainide (Compound) causes Shock (Side Effect)